Printer Friendly

SUPRA MEDICAL EXPANDS NON-INVASIVE BREAST DISEASE DIAGNOSTIC PROGRAM

 CHADDS FORD, Pa., June 10 /PRNewswire/ -- Supra Medical Corp. (AMEX: SUM.EC) revealed today that it was accelerating its research and development activities in the non-invasive diagnosis of breast disorders.
 Until recently, the company's ultrasound efforts were devoted exclusively to the diagnosis and monitoring of skin disorders.
 Yesterday, the Supra Medical board of directors voted to acquire from Evelyna Dyson-Cantwell, the company's president, the ownership rights to her exclusive, personal breast diagnostic work that preceded the company's acquisition of the Cantwell's ultrasound technology in November 1991. The board approved payment to her in shares of restricted company stock plus a running royalty on breast diagnostic products. Precise terms of the agreement were not revealed. Dyson-Cantwell also agreed to a five-year employment/non-compete contract with the company.
 Prior to her present association, Dyson-Cantwell spent eight years researching breast disorder diagnostics with several recognized university medical specialists and in collaborations with leading practitioners. This self-financed activity yielded extensive invention, equipment, expertise, schematic drawings, diagrams, patient data, and market research. She gained practical experience through clinical research which contributed substantially to the development of these technologies which included promising modalities other than ultrasound.
 Jack Cantwell, chairman, commented, "The medical need is urgent and the potential market substantial. These new assets plus the contributions of our strategic partners, National Aeronautics and Space Administration (NASA) and the United Medical and Dental Schools of Guy's and St. Thomas's Hospitals, London, will speed our current progress in breast disorder diagnostics."
 Supra Medical Corp. develops and markets proprietary medical products which are used in the diagnosis, monitoring and ongoing treatment of skin disorders including skin cancers, burns and various wounds.
 For additional information, contact George J. Stasen, chief operating officer and executive vice president, Supra Medical Corp., Chadds Ford, 800-388-6769.
 /delval/
 -0-
 /CONTACT: George J. Stasen, COO/EVP of Supra Medical, 800-388-6769/
 (SUM)


CO: Supra Medical Corp. ST: Pennsylvania IN: HEA SU:

JM-MK -- PH009 -- 0565 06/10/93 11:11 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 10, 1993
Words:323
Previous Article:NETWORK IMAGING SIGNS AGREEMENT WITH DICKENS DATA VALUED AT $25 MILLION
Next Article:TASTY BAKING COMPANY FILES FOR SPIN OFF OF SUBSIDIARY
Topics:


Related Articles
SUPRA MEDICAL REVEALS NEW ULTRASOUND SCANNER
SUPRA MEDICAL CORP. RELEASES FIRST QUARTER RESULTS
PORTABLE VERSION OF SUPRA SCANNER(R) SLASHES COSTS AND BROADENS MARKET
/C O R R E C T I O N -- SUPRA MEDICAL/
SUPRA MEDICAL CORP. RESTRUCTURES AND ADDS MANAGEMENT PERSONNEL
SUPRA MEDICAL CORP. RELEASES THIRD QUARTER RESULTS
SUPRA MEDICAL CORP. AND SONIX, INC. ANNOUNCE ULTRASOUND COLLABORATIVE EFFORT
SUPRA MEDICAL REALIGNS MANAGEMENT
CYTOGEN INITIATES CLINICAL TRIALS FOR BREAST CANCER
MEDICAL GRAPHICS CORPORATION AWARDED PURCHASING CONTRACT

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters